A West Virginia coverage pilot exposed the cost of stopping a benefit

West Virginia's public-employee insurance agency ended a limited pilot that had covered obesity medicines for state workers after citing budget pressure. The program reached about 1,000 people at its peak and showed how a payer decision can change the terms of access for people already enrolled.

The household consequence was not abstract: former participants faced the loss of a covered benefit while the state weighed a roughly $15 million annual pilot cost against a far larger potential expansion. That conflict sits at the center of public coverage design when a recurring medicine serves a large eligible population.

This episode does not settle what any insurer should cover or predict an individual outcome. It shows the difference between a program's institutional budget calculation and the lived disruption that follows when coverage ends.

Read the full story at The Atlantic ↗